Advertisement
Advertisement
U.S. markets close in 4 hours
Advertisement
Advertisement
Advertisement
Advertisement

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.06+0.85 (+7.58%)
As of 12:00PM EDT. Market open.
Advertisement

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees858

Key Executives

NameTitlePayExercisedYear Born
Mr. Chad M. Robins M.B.A, M.B.A.Co-Founder, CEO & Chairman1.16MN/A1975
Ms. Julie RubinsteinPres754.04k31.96M1972
Dr. Harlan S. Robins Ph.D.Co-Founder & Chief Scientific Officer753.7k12.83M1973
Mr. Nitin SoodChief Commercial Officer of MRD548.07kN/AN/A
Mr. Christopher Carlson Ph.D.FounderN/AN/AN/A
Mr. Tycho W. PetersonChief Financial OfficerN/AN/AN/A
Dr. Mark AdamsCOO & CTON/AN/A1967
Mr. Kyle PiskelPrincipal Accounting OfficerN/AN/A1984
Karina CalzadillaVP of Investor RelationsN/AN/AN/A
Ms. Stacy L. TaylorSr. VP & Gen. CounselN/AN/A1960
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Corporate Governance

Adaptive Biotechnologies Corporation’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement